Overview

A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia

Status:
Completed

Trial end date:
2020-12-12

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan) compared to standard of care (SOC), with respect to clinical status assessed by a 7-point ordinal scale in hospitalized adult patients diagnosed with COVID-19 pneumonia

Phase:

Phase 2

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical

Treatments:

Nafamostat